TL;DR: Blocking DUSP6 protein alongside ketamine extends antidepressant effects from 2 weeks to 4+ weeks in mice, potentially offering single-dose treatment instead of repeated infusions. Ketamine works like almost nothing else in psychiatry. A single infusion can lift severe depression within hours, even in patients who’ve failed every other drug. The problem? The magic doesn’t …
TL;DR: Young adults with depression produce ATP—the cell’s energy currency—at faster rates in both brain and blood, yet still feel more fatigued. New research reveals this is a compensatory mechanism that works at rest but collapses under stress, opening a fresh window into the biology of depression-related fatigue. Fatigue in major depression is relentless and …
TL;DR: A massive study of 27.8 million Medicare beneficiaries found that exposure to fine air pollution (PM2.5) increases Alzheimer’s risk by 8.5% per unit increase—and this effect operates largely through direct brain damage, not through common health conditions like stroke or depression. The conventional thinking about air pollution and dementia involves a detour through the …
TL;DR: Microplastics circulating in your blood may accelerate Alzheimer’s and Parkinson’s disease through six shared pathways—including blood-brain barrier breakdown, chronic inflammation, and oxidative stress. You probably know plastic pollution is everywhere. Less obvious: tiny plastic fragments are crossing into your brain, accumulating in brain tissue, and potentially triggering neurodegenerative disease. A new review in Molecular …
TL;DR: Aerobic exercise matches antidepressant efficacy for depression with effect size −1.60, resistance training slightly edges aerobic for anxiety, and neither requires meeting WHO guidelines—20 minutes three times weekly still produces clinical improvement. Depression responds to a treatment that’s free, legal, and accessible: exercise. But the type matters profoundly. A comprehensive meta-analysis of 26 randomized …
TL;DR: Chemists designed a new psilocin derivative with fluorine modifications that induces sub-hallucinogenic effects in mice, sidestepping the acute psychological effects of classic psychedelics while retaining therapeutic serotonin receptor activity. Psilocybin has emerged as a clinical darling—mounting evidence shows rapid relief for depression, anxiety, and cluster headaches. But there’s a catch: the intense hallucinations and …
TL;DR: TDP43, the protein that misfires in ALS and FTD, secretly controls DNA repair genes—and when it breaks, mutations pile up in neurons, potentially explaining both neurodegeneration and the cancer link in these diseases. A protein known for its role in neurodegenerative disease has a hidden job: keeping the cell’s DNA repair crew on task. …
TL;DR: A blood test measuring phosphorylated tau-217 can predict when cognitively normal people will develop Alzheimer’s symptoms with a 3.0-3.7 year margin of error, potentially transforming how researchers identify candidates for preventive clinical trials. For decades, Alzheimer’s disease remained invisible until symptoms emerged. Brain scans could show amyloid plaques and tau tangles, but only in …
TL;DR: A new blood test using three misfolded plasma proteins can identify Alzheimer’s disease with 83.44% accuracy, outperforming conventional biomarkers and offering a non-invasive screening tool years before cognitive symptoms appear. The holy grail of Alzheimer’s research isn’t a cure—yet. It’s catching the disease before memory starts to fade. By the time someone notices confusion, …
TL;DR: A newly decoded proton channel called TMEM175 lies dormant in lysosomes until acid arrives—then it opens wide and floods the cell with hydrogen ions, disrupting the delicate pH balance linked to Parkinson’s disease and other neurodegeneration. Your cells run a 24/7 recycling system inside tiny acid baths called lysosomes — and when those baths …
